DOC Earnings

DOC reported its earnings on 2026-02-02, showcasing a revenue of 719.40M against an estimate of 699.52M, resulting in a 2.84% surprise. The EPS was 0.47, surpassing the expected 0.45 by 4.44%. The stock experienced a -2.78% price change on the earnings day and a -0.41% change over the next five days, reflecting market reactions to the results.

Following DOC's earnings announcement on 2026-02-02, the stock price moved by -2.78% on the day of the release. Over the subsequent five days, it saw a -0.41% change. Historically, DOC's stock price tends to shift by an average of -1.04% in the 10 days leading up to earnings and -2.17% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate DOC's annual revenue to reach 685.13M, while the EPS is projected at 0.07. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.02% over the past three months, indicating analyst expectation in the company's performance.

The correlation between DOC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.02%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DOC's stock price typically moves by -1.04% in the 10 days before its earnings and -2.17% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.07 and revenue of 685.13M.

The earnings call reveals mixed signals: positive trends in the life science sector and strategic moves in outpatient medical and technology initiatives, but concerns over occupancy declines, lab segment challenges, and uncertain FFO outlook. The Q&A section highlights management's avoidance of specific details, which may raise investor skepticism. Given the lack of strong catalysts and management's cautious tone, the stock price is likely to remain stable, resulting in a neutral sentiment.